Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT07118592
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cardiometabolic Diseases
  • Hypertension (HTN)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Low Salt Diet — DIETARY_SUPPLEMENT
    8 days of diet with low salt content will be given to the study participants
  • High Salt Diet — DIETARY_SUPPLEMENT
    8 days of diet with high salt content will be given to the study participants
  • Saline Infusion — DIETARY_SUPPLEMENT
    2 Liters of normal saline infusion (0.25 ml/kg/min over 2 hours) will be given to the study participants at the end of each study period

Study Details

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

Key Dates

Start date
Sep 1, 2026
Status verified
Mar 2026
Primary completion
Jun 1, 2030
Completion
Dec 1, 2030

Study Design

Enrollment
200 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION

Arms

  • Experimental: High Natriuretic Peptide Polygenic Score
    Active Comparator: High NP PGS Group
  • Experimental: Low Natriuretic Peptide Polygenic Score
    Experimental: Low NP PGS Group

Primary Outcome Measure

Change in 24h mean Systolic Blood Pressure (SBP) [ Time Frame: 3 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294-

Find similar trials in Birmingham, AL

By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies